Session

IBD (Posters)

CAN DYSPLASIA SURVEILLANCE BE BETTER TARGETED BY USING FAECAL CALPROTECTIN MEASUREMENTS IN ULCERATIVE COLITIS?
CAN DYSPLASIA SURVEILLANCE BE BETTER TARGETED BY USING FAECAL CALPROTECTIN MEASUREMENTS IN ULCERATIVE COLITIS?

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

BIFIDOBACTERIUM LONGUM NCC3001 PROMOTES COLONIC TISSUE REPAIR VIA PHOSPHOLIPID METABOLISM AND THE PURINE SALVAGE PATHWAY IN EXPERIMENTAL CHRONIC COLITIS
BIFIDOBACTERIUM LONGUM NCC3001 PROMOTES COLONIC TISSUE REPAIR VIA PHOSPHOLIPID METABOLISM AND THE PURINE SALVAGE PATHWAY IN EXPERIMENTAL CHRONIC COLITIS

ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN'S DISEASE
ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN'S DISEASE

REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER
REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

RESULTS FROM A LARGE SURVEY EXPLORING PATIENT PREFERENCES FOR TREATMENT ATTRIBUTES IN INFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES IN EUROPE
RESULTS FROM A LARGE SURVEY EXPLORING PATIENT PREFERENCES FOR TREATMENT ATTRIBUTES IN INFLAMMATORY BOWEL DISEASE ACROSS 7 COUNTRIES IN EUROPE

THERAPEUTIC TARGETS IN PAEDIATRIC IBD: A RETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALS BASED ON UPDATED STRIDE-II (SELECTING THERAPEUTIC TARGETS IN INFLAMMATORY BOWEL DISEASE) RECOMMENDATIONS
THERAPEUTIC TARGETS IN PAEDIATRIC IBD: A RETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALS BASED ON UPDATED STRIDE-II (SELECTING THERAPEUTIC TARGETS IN INFLAMMATORY BOWEL DISEASE) RECOMMENDATIONS

ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS
ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS

INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY
INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY

GROUP-BASED TRAJECTORY ANALYSIS OF WEIGHT CHANGE IN AN INFLIXIMAB-TREATED COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
GROUP-BASED TRAJECTORY ANALYSIS OF WEIGHT CHANGE IN AN INFLIXIMAB-TREATED COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

SMALL-BOWEL ANGIOECTASIA: DO THE FEATURES AND APPROACH REALLY MATTER?
SMALL-BOWEL ANGIOECTASIA: DO THE FEATURES AND APPROACH REALLY MATTER?

ULTRASONOGRAPHIC SCORES FOR CROHN'S DISEASE ACTIVITY ASSESSMENT - STILL LAG BEHIND CEUS
ULTRASONOGRAPHIC SCORES FOR CROHN'S DISEASE ACTIVITY ASSESSMENT - STILL LAG BEHIND CEUS

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN'S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN'S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

TELEMEDICINE IS AN EFFECTIVE TOOL TO MONITOR DISEASE ACTIVITY IN IBD PATIENTS IN THE COVID-19 ERA: A SINGLE CENTRE EXPERIENCE BASED ON OBJECTIVE DATA
TELEMEDICINE IS AN EFFECTIVE TOOL TO MONITOR DISEASE ACTIVITY IN IBD PATIENTS IN THE COVID-19 ERA: A SINGLE CENTRE EXPERIENCE BASED ON OBJECTIVE DATA

LOCAL MESENCHYMAL STEM CELLS INJECTION IN CROHN'S DISEASE STRICTURES: A PHASE I-II CLINICAL STUDY
LOCAL MESENCHYMAL STEM CELLS INJECTION IN CROHN'S DISEASE STRICTURES: A PHASE I-II CLINICAL STUDY

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY
DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY

RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT
RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Item 141 - 160 / 568
1 2 3 4 5 6 7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29